Exhibit 10.2

AMENDMENT 2

to the

PATENT ASSIGNMENT AGREEMENT

This Amendment 2, by and between SpinalCyte LLC, a Texas limited liability company (“SpinalCyte”), and FibroBiologics, Inc., a Delaware corporation (“FibroBiologics”), (“Amendment 2”), amends the Patent Assignment Agreement dated May 17, 2021, entered into by and between SpinalCyte and FibroBiologics (as amended, the “Assignment”), and is effective as of May 17, 2021 (“Effective Date”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, SpinalCyte is the owner of all right title and interest in and to certain Patents, as defined in the Assignment;

WHEREAS, FibroBiologics is further developing Patents obtained from SpinalCyte through the Assignment;

WHEREAS, FibroBiologics purchased and received from SpinalCyte all right, title and interest in the Patents through the Assignment; and

WHEREAS, the Parties inadvertently omitted certain patents and patent applications from Exhibit A to the Assignment and now SpinalCyte wishes to transfer all right, title and interest in the omitted patents and patent applications to FibroBiologics for further development.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

All other terms and conditions of the Assignment shall remain in full force and effect and no other changes are made as a result of this Amendment 2.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment 2 to be executed by their duly authorized officers to be effective as of the Effective Date.